AGC (Japan), a world-leading manufacturer of glass, chemicals and high-tech materials, has announced that it has entered into an agreement with Boehringer Ingelheim to acquire Malgrat Pharma Chemicals (MPC).
MPC is a subsidiary of Boehringer Ingelheim that manufactures synthetic pharmaceutical active ingredients for the group. AGC will have its first FDA-registered site in Europe in the synthetic pharmaceutical CDMO business. MPC has vast experience manufacturing cGMP-compliant commercialized synthetic pharmaceuticals as well as compounds in clinical development on a range of scales.
Leveraging AGC’s fluorination technologies and extensive experience in in-house drug discovery and the CDMO business built up in Japan, AGC, with the addition of MPC, will be able to offer its CDMO services expanding its presence in the European market.
AGC became the world’s largest glass manufacturer. The company is headquartered in Tokyo, Japan.